Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 14, 2024
Reporting Period: Event date April 14, 2024; Signed April 18, 2024.
Context: The Company is an emerging growth company incorporated in Delaware, trading on NYSE American under the symbols CLDI (Common Stock) and CLDIWS (Warrants).
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The only specific financial figure disclosed relates to a debt instrument:
- Convertible Note Principal: $1.5 million (issued March 8, 2024, amended April 14, 2024).
- Debt Status: The note was issued in settlement of an unasserted claim.
Material Changes
The primary material change reported is the amendment of a $1.5 million convertible note entered into on March 8, 2024. The amendment, effective April 14, 2024, establishes a specific repayment mechanism:
- If the noteholder participates in a registered public offering under the same terms as other investors for an amount equal to the principal ($1.5 million), the proceeds from that sale will be used to pay off the Note.
Guidance, Outlook, and Risks
Management Commentary: The filing references a previously disclosed settlement agreement regarding an unasserted claim. No forward-looking guidance, revenue outlook, or strategic commentary is provided in this specific report.
Risks and Contingencies: The filing notes that certain information in the attached exhibit has been omitted as it is considered private or confidential. The existence of the settlement agreement itself implies a prior legal contingency that has been resolved via the issuance of the note.
Investor Verification Checklist
- Verify the terms of the "Third Amendment to $1,500,000 Convertible Note" (Exhibit 10.1) to understand the full conditions for repayment via a public offering.
- Review the referenced Form S-1 (File No. 333-276741) for the complete text of the Amendment and details on the unasserted claim settlement.
- Monitor upcoming filings for any registered public offerings that might trigger the repayment clause of the $1.5 million note.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K, as this 8-K does not provide liquidity data.